Nyxoah SA (NAS:NYXH)
$ 8 -0.255 (-3.09%) Market Cap: 303.85 Mil Enterprise Value: 253.25 Mil PE Ratio: 0 PB Ratio: 2.44 GF Score: 59/100

Nyxoah SA at Oppenheimer Healthcare Conference (Virtual) Transcript

Mar 17, 2021 / 12:40PM GMT
Suraj Kalia
Oppenheimer & Co. Inc., Research Division - MD & Senior Analyst

Good morning, everyone. This is Suraj Kalia. I'm the senior medical device analyst at Oppenheimer. Pleased to have all of you join us this morning, the second day of the Oppenheimer Annual Healthcare Conference. I am truly pleased to have a unique company start off the day on our side, which is Nyxoah. They are doing some very interesting stuff in obstructive sleep apnea, and I'll let the company talk about it.

Presenting this morning are Olivier Taelman, CEO. Olivier, it's a pleasure to have you. I'll let you take the floor from here.

Olivier Taelman
Nyxoah S.A. - Executive Director & CEO

Okay. Thank you, Suraj, and thank you to the Oppenheimer team for having us and allowing us to share the Nyxoah story. So -- sorry we are -- so maybe I should start with a brief introduction of myself and also Fabian Suarez, our CFO.

So I'm Olivier Taelman, I'm born and raised in Belgium. I spent more than 20 years in the med tech industry, of which almost 10 years

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot